All Videos

Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.

Panelists discuss how health care providers must balance the convenience and accessibility of telemedicine with individual patient needs and clinical considerations when delivering dermatological care.

Panelists discuss how atopic dermatitis significantly impacts patients' mental health, social relationships, and daily activities, creating substantial psychosocial burdens that can lead to anxiety, depression, and reduced quality of life.

Panelists discuss how atopic dermatitis impacts different demographic groups through variations in disease presentation, treatment access, and quality of life outcomes.

Panelists discuss how spesolimab dosing regimens are tailored to individual patient needs, with an initial high-dose infusion followed by maintenance therapy based on clinical response and disease severity.

Panelists discuss how advanced basal cell carcinoma (BCC) management requires a nuanced approach, emphasizing the importance of early detection, multidisciplinary collaboration, personalized treatment strategies, and ongoing patient monitoring to optimize outcomes and quality of life.

Andrew Alexis, MD, MPH, discusses how, in creating individualized treatment plans for vitiligo, clinicians must carefully consider the distinct challenges and response patterns associated with segmental vs nonsegmental forms, as segmental vitiligo tends to be more stable after initial progression but often more resistant to treatment, while nonsegmental vitiligo typically shows a more unpredictable course requiring ongoing management strategies.

The panelist discusses the primary challenges in vitiligo repigmentation, including maintaining patient compliance through lengthy treatment courses and managing expectations around partial repigmentation outcomes, which require careful monitoring and ongoing patient education about realistic goals while assessing success through standardized documentation of even minimal improvements to inform treatment adjustments.

Andrew Alexis, MD, MPH, discusses how holistic management of vitiligo requires addressing both the physical and psychological impact through empathetic counseling and support groups while setting realistic treatment expectations and timelines with patients through clear communication about repigmentation goals, potential outcomes, and available therapeutic options.

Panelists discuss how setting long-term treatment goals for basal cell carcinoma (BCC) patients involves balancing factors such as disease control, quality of life, and potential adverse reactions to create personalized management plans that address both immediate concerns and future outcomes.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Lisa Swanson, MD, discusses how telemedicine and digital health tools can aid in the management and follow-up care of pediatric patients with vitiligo by enabling remote monitoring, improving access to specialists, and facilitating patient engagement, while emerging research into vitiligo treatments may focus on developing therapies to halt or slow the progression of this autoimmune skin condition.

The panelist discusses advances in targeted therapies, including novel biologics and small molecules, as well as the development of personalized treatment approaches tailored to individual patient characteristics, which hold great promise for improving outcomes and enhancing the quality of life for children living with vitiligo in the future.

Lisa Swanson, MD, discusses providing educational resources and materials that explain vitiligo, dispel myths, and promote understanding.

Tiffany Mayo, MD, highlights the treatment guidelines in management of patients with hidradenitis suppurativa and discusses the role of biologics in the treatment landscape.

Tiffany Mayo, MD, shares insights regarding disease severity and the role of progression of hidradenitis suppurativa.

Tiffany Mayo, MD, provides an overview of hidradenitis suppurativa and discusses the patient burden and challenges to diagnosis of the disease.

Tiffany Mayo, MD, provides insights and practical tips in patient communication for the diagnosis and management of patients with hidradenitis suppurativa.

Panelists discuss how a complex case of advanced basal cell carcinoma (BCC) demonstrates the necessity for collaborative care across multiple specialties, highlighting the importance of tailored treatment strategies and coordinated management to achieve the best possible patient outcomes.

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gaps in atopic dermatitis management for various patient subgroups.

Michael Lewitt, MD, discusses a case involving a 7-year-old girl with plaque psoriasis (PsO) affecting body surface area (BSA) and the face, emphasizing the limited pediatric treatment options and the psychological and social impact on the child; the family initially opted for topical treatments like roflumilast, but preferred a more proactive approach, transitioning to apremilast while addressing concerns about gastrointestinal adverse events and the patient’s aversion to needles.

Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.

Michael Lewitt, MD, provides an overview of Case-Based Roundtable and introduces a case involving a patient with a 10-year history of plaque psoriasis (PsO) in sensitive areas, discussing the significant impact on quality of life, the patient’s aversion to needles as a new mom, and the exploration of biologic therapies as a treatment option.

Panelists discuss how a multidisciplinary approach involving dermatologists, surgeons, radiation oncologists, and medical oncologists is crucial for optimal decision-making and management of complex basal cell carcinoma (BCC) cases, ensuring comprehensive care and improved patient outcomes.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.